|
1
|
Ali AT: Risk factors for endometrial
cancer. Ceska Gynekol. 78:448–459. 2013.PubMed/NCBI
|
|
2
|
Corzo C, Barrientos Santillan N, Westin SN
and Ramirez PT: Updates on conservative management of endometrial
cancer. J Minim Invasive Gynecol. 25:308–313. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kalogera E, Dowdy SC and Bakkum-Gamez JN:
Preserving fertility in young patients with endometrial cancer:
Current perspectives. Int J Womens Health. 6:691–701.
2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Peiretti M, Congiu F, Ricciardi E,
Maniglio P, Mais V and Angioni S: Conservative treatment for
well-differentiated endometrial cancer: When and why it should be
considered in young women. Ecancermedicalscience.
13(892)2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Oaknin A, Bosse TJ, Creutzberg CL,
Giornelli G, Harter P, Joly F, Lorusso D, Marth C, Makker V, Mirza
MR, et al: Endometrial cancer: ESMO clinical practice guideline for
diagnosis, treatment and follow-up. Ann Oncol. 33:860–877.
2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Braun MM, Overbeek-Wager EA and Grumbo RJ:
Diagnosis and management of endometrial cancer. Am Fam Physician.
93:468–474. 2016.PubMed/NCBI
|
|
7
|
Obermair A, Baxter E, Brennan DJ, McAlpine
JN, Mueller JJ, Amant F, van Gent MDJM, Coleman RL, Westin SN,
Yates MS, et al: Fertility-sparing treatment in early endometrial
cancer: Current state and future strategies. Obstet Gynecol Sci.
63:417–431. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Trojano G, Olivieri C, Tinelli R, Damiani
GR, Pellegrino A and Cicinelli E: Conservative treatment in early
stage endometrial cancer: A review. Acta Biomed. 90:405–410.
2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Moore K and Brewer MA: Endometrial cancer:
Is this a new disease? Am Soc Clin Oncol Educ Book. 37:435–442.
2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Rodolakis A, Biliatis I, Morice P, Reed N,
Mangler M, Kesic V and Denschlag D: European society of
gynecological oncology task force for fertility preservation:
Clinical recommendations for fertility-sparing management in young
endometrial cancer patients. Int J Gynecol Cancer. 25:1258–1265.
2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sundar S, Balega J, Crosbie E, Drake A,
Edmondson R, Fotopoulou C, Gallos I, Ganesan R, Gupta J, Johnson N,
et al: BGCS uterine cancer guidelines: Recommendations for
practice. Eur J Obstet Gynecol Reprod Biol. 213:71–97.
2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Saleh M, Virarkar M, Bhosale P, El Sherif
S, Javadi S and Faria SC: Endometrial cancer, the current
international federation of gynecology and obstetrics staging
system, and the role of imaging. J Comput Assist Tomogr.
44:714–729. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Concil N, Matias-Guiu X, Vergote I, Cibula
D, Mirza MR, Marnitz S, Ladermann J, Bosse T, Chargari C, Fagotti
A, et al: ESGO/ESTRO/ESP guidelines for the management of patients
with endometrial carcinoma. Int J Gynecol Cancer. 31:12–39.
2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Terzic M, Norton M, Terzic S, Bapayeva G
and Aimagambetova G: Fertility preservation in endometrial cancer
patients: Options, challenges and perspectives.
Ecancermedicalscience. 14(1030)2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Creasman WT, Morrow CP, Bundy BN, Homesley
HD, Graham JE and Heller PB: Surgical pathologic spread patterns of
endometrial cancer. A gynecologic oncology group study. Cancer. 60
(8 Suppl):S2035–S2041. 1987.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gonthier C, Douhnai D and Koskas M: Lymph
node metastasis probability in young patients eligible for
conservative management of endometrial cancer. Gynecol Oncol.
157:131–135. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Dijkhuizen FP, Mol BW, Brölmann HA and
Heintz AP: The accuracy of endometrial sampling in the diagnosis of
patients with endometrial carcinoma and hyperplasia: A
meta-analysis. Cancer. 89:1765–1772. 2000.PubMed/NCBI
|
|
18
|
Leitao MM Jr, Kehoe S, Barakat RR,
Alektiar K, Gattoc LP, Rabbitt C, Chi DS, Soslow RA and Abu-Rustum
NR: Comparison of D&C and office endometrial biopsy accuracy in
patients with FIGO grade 1 endometrial adenocarcinoma. Gynecol
Oncol. 113:105–108. 2009.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Casadio P, La Rosa M, Alletto A,
Magnarelli G, Arena A, Fontana E, Fabbri M, Giovannico K, Virgilio
A, Raimondo D, et al: Fertility sparing treatment of endometrial
cancer with and without initial infiltration of myometrium: A
single center experience. Cancers (Basel). 12(3571)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Gkorzou F, Dimakopoulos G, Vrekoussis T,
Lavasidis L, Koutlas A, Navrozoglou I, Stefos T and Paschopoulos M:
Hysteroscopy in women with abnormal uterine bleeding: A
meta-analysis on four major endometrial pathologies. Arch Gynecol
Obstet. 291:1347–1354. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Frei KA, Kinkel K, Bonél HM, Lu Y,
Zaloudek C and Hricak H: Prediction of deep myometrial invasion in
patients with endometrial cancer: Clinical utility of
contrast-enhanced MR imaging-a meta-analysis and Bayesian analysis.
Radiology. 216:444–449. 2000.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Alcázar JL, Gastón B, Navarro B, Salas R,
Aranda J and Guerriero S: Transvaginal ultrasound versus magnetic
resonance imaging for preoperative assessment of myometrial
infiltration in patients with endometrial cancer: A systematic
review and meta-analysis. J Gynecol Oncol. 28(e86)2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Yang T, Tian S, Li Y, Tian X, Wang W, Zhao
J, Pei M, Zhao M, Wang L, Quan S and Yang X: Magnetic resonance
imaging (MRI) and three-dimensional transvaginal ultrasonography
scanning for preoperative assessment of high risk in women with
endometrial cancer. Med Sci Monit. 25:2024–2031. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Rodolakis A, Scambia G, Planchamp F, Acien
M, Di Spiezio Sardo A, Farrugia M, Grynberg M, Pakiz M, Pavlakis K,
Vermeulen N, et al: ESGO/ESHRE/ESGE guidelines for the
fertility-sparing treatment of patients with endometrial carcinoma.
Int J Gynecol Cancer. 33:208–222. 2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Alonso S, Castellanos T, Lapuente F and
Chiva L: Hysteroscopic surgery for conservative management in
endometrial cancer: A review of the literature.
Ecancermedicalscience. 9(505)2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Chae-Kim J, Garg G, Gavrilova-Jordan L,
Blake LE, Kim TT, Wu Q and Hayslip CC: Outcomes of women treated
with progestin and metformin for atypical endometrial hyperplasia
and early endometrial cancer: A systematic review and
meta-analysis. Int J Gynecol Cancer. 31:1499–1505. 2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Mitsuhashi A, Habu Y, Kobayashi T, Kawarai
Y, Ishikawa H, Usui H and Shozu M: Long-term outcomes of progestin
plus metformin as a fertility-sparing treatment for atypical
endometrial hyperplasia and endometrial cancer patients. J Gynecol
Oncol. 30(e90)2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Sidorkiewicz I, Jóźwik M, Niemira M and
Krętowski A: Insulin resistance and endometrial cancer: Emerging
role for microRNA. Cancers (Basel). 12(2559)2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wang Y and Yang JX: Fertility-preserving
treatment in women with early endometrial cancer: The Chinese
experience. Cancer Manag Res. 10:6803–6813. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Park JY and Nam JH: Progestins in the
fertility-sparing treatment and retreatment of patients with
primary and recurrent endometrial cancer. Oncologist. 20:270–278.
2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Shao R: Progesterone receptor isoforms A
and B: New insights into the mechanism of progesterone resistance
for the treatment of endometrial carcinoma. Ecancermedicalscience.
7(381)2013.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Cavaliere AF, Perelli F, Zaami S,
D'Indinosante M, Turrini I, Giusti M, Gullo G, Vizzielli G, Mattei
A, Scambia G, et al: Fertility sparing treatments in endometrial
cancer patients: The potential role of the new molecular
classification. Int J Mol Sci. 22(12248)2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Garzon S, Uccella S, Zorzato PC, Bosco M,
Franchi MP, Student V and Mariani A: Fertility-sparing management
for endometrial cancer: Review of the literature. Minerva Med.
112:55–69. 2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ruiz MP, Huang Y, Hou JY, Tergas AI, Burke
WM, Ananth CV, Neugut AI, Hershman DL and Wright JD: All-cause
mortality in young women with endometrial cancer receiving
progesterone therapy. Am J Obstet Gynecol. 217:669.e1–669.e13.
2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Travaglino A, Raffone A, Saccone G,
Insabato L, Mollo A, De Placido G and Zullo F: Immunohistochemical
predictive markers of response to conservative treatment of
endometrial hyperplasia and early endometrial cancer: A systematic
review. Acta Obstet Gynecol Scand. 98:1086–1099. 2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Knez J, Al Mahdawi L, Takač I and Sobočan
M: The perspectives of fertility preservation in women with
endometrial cancer. Cancers (Basel). 13(602)2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Pal N, Broaddus RR, Urbauer DL,
Balakrishnan N, Milbourne A, Schmeler KM, Meyer LA, Soliman PT, Lu
KH, Ramirez PT, et al: Treatment of low-risk endometrial cancer and
complex atypical hyperplasia with the levonorgestrel-releasing
intrauterine device. Obstet Gynecol. 131:109–116. 2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Yang BY, Gulinazi Y, Du Y, Ning CC, Cheng
YL, Shan WW, Luo XZ, Zhang HW, Zhu Q, Ma FH, et al: Metformin plus
megestrol acetate compared with megestrol acetate alone as
fertility-sparing treatment in patients with atypical endometrial
hyperplasia and well-differentiated endometrial cancer: A
randomised controlled trial. BJOG. 127:848–857. 2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Chen X: The current situation of the
levonorgestrel intrauterine system (LNG-IUS) in conservative
treatment for patients with early-stage endometrial cancer and
atypical hyperplasia. J Gynecol Oncol. 30(e79)2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Xu Z, Yang B, Guan J, Shan W, Liao J, Shao
W and Chen X: Comparison of the effect of oral megestrol acetate
with or without levonorgestrel-intrauterine system on
fertility-preserving treatment in patients with early-stage
endometrial cancer: A prospective, open-label, randomized control
phase II trial (urihttp://ClinicalTrials.govsimpleClinicalTrials.gov
NCT03241914). J Gynecol Oncol. 34(e32)2023.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Uccella S, Zorzato PC, Dababou S, Bosco M,
Torella M, Braga A, Frigerio M, Gardella B, Cianci S, Laganà AS, et
al: Conservative management of atypical endometrial hyperplasia and
early endometrial cancer in childbearing age women. Medicina
(Kaunas). 58(1256)2022.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Lee TY, Martinez-Outschoorn UE, Schilder
RJ, Kim CH, Richard SD, Rosenblum NG and Jonshon JM: Metformin as a
therapeutic target in endometrial cancers. Front Oncol.
8(341)2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Li X, Fan Y and Wang J, Zhou R, Tian L,
Wang Y and Wang J: Insulin resistance and metabolic syndrome
increase the risk of relapse for fertility preserving treatment in
atypical endometrial hyperplasia and early endometrial cancer
patients. Front Oncol. 11(744689)2021.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Zhao X, Niu J, Shi C and Liu Z:
Levonorgestrel-releasing intrauterine device plus metformin, or
megestrol acetate plus metformin for fertility-sparing treatment of
atypical endometrial hyperplasia and early endometrial carcinoma: A
prospective, randomized, blind-endpoint design trial protocol.
Reprod Health. 19(206)2022.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Mazzon I, Corrado G, Masciullo V,
Morricone D, Ferrandina G and Scambia G: Conservative surgical
management of stage IA endometrial carcinoma for fertility
preservation. Fertil Steril. 93:1286–1289. 2010.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Giampaolino P, Di Spiezio Sardo A, Mollo
A, Raffone A, Travaglino A, Boccellino A, Zizolfi B, Insabato L,
Zullo F, De Placido G and Bifulco G: Hysteroscopic endometrial
focal resection followed by levonorgestrel intrauterine device
insertion as a fertility-sparing treatment of atypical endometrial
hyperplasia and early endometrial cancer: A retrospective study. J
Minim Invasive Gynecol. 26:648–656. 2019.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Yang B, Xu Y, Zhu Q, Xie L, Shan W, Ning
C, Xie B, Shi Y, Luo X, Zhang H and Chen X: Treatment efficiency of
comprehensive hysteroscopic evaluation and lesion resection
combined with progestin therapy in young women with endometrial
atypical hyperplasia and endometrial cancer. Gynecol Oncol.
153:55–62. 2019.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Lucchini SM, Esteban A, Nigra MA, Palacios
AT, Alzate-Granados JP and Borla HF: Updates on conservative
management of endometrial cancer in patients younger than 45 years.
Gynecol Oncol. 161:802–809. 2021.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Carneiro MM, Lamaita RM, Ferreira MCF and
Silva-Filho AL: Fertility-preservation in endometrial cancer: Is it
safe? Review of the literature. JBRA Assist Reprod. 20:232–239.
2016.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Mutlu L, Manavella DD, Gullo G, McNamara
B, Santin AD and Patrizio P: Endometrial Cancer in Reproductive
Age: Fertility-Sparing Approach and Reproductive Outcomes. Cancers
(Basel). 14(5187)2022.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Harrison RF, He W, Fu S, Zhao H, Sun CC,
Suidan RS, Woodard TL, Rauh-Hain A, Westin SN, Giordano SH and
Meyer LA: National patterns of care and fertility outcomes for
reproductive-aged women with endometrial cancer or atypical
hyperplasia. Am J Obstet Gynecol. 221:474.e1–474.e11.
2019.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Fan Y, Li X and Wang J, Wang Y, Tian L and
Wang J: Analysis of pregnancy-associated factors after
fertility-sparing therapy in young women with early stage
endometrial cancer or atypical endometrial hyperplasia. Reprod Biol
Endocrinol. 19(118)2021.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Herrera Cappelletti E, Humann J, Torrejón
R and Gambaduaro P: Chances of pregnancy and live birth among women
undergoing conservative management of early-stage endometrial
cancer: A systematic review and meta-analysis. Hum Reprod Update.
28:282–295. 2022.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Chao AS, Chao A, Wang CJ, Lai CH and Wang
HS: Obstetric outcomes of pregnancy after conservative treatment of
endometrial cancer: Case series and literature review. Taiwan J
Obstet Gynecol. 50:62–66. 2011.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Britton H, Huang L, Lum A, Leung S, Shum
K, Kale M, Burleigh A, Senz J, Yang W, McConechy M, et al:
Molecular classification defines outcomes and opportunities in
young women with endometrial carcinoma. Gynecol Oncol. 153:487–495.
2019.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Ronsini C, Mosca L, Iavarone I, Nicoletti
R, Vinci D, Carotenuto RM, Pasanisi F, Solazzo MC, De Franciscis P,
Torella M, et al: Oncological outcomes in fertility-sparing
treatment in stage IA-G2 endometrial cancer. Front Oncol.
12(965029)2022.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Falcone F, Leone Roberti Maggiore U, Di
Donato V, Perrone AM, Frigerio L, Bifulco G, Polterauer S, Casadio
P, Cormio G, Masciullo V, et al: Fertility-sparing treatment for
intramucous, moderately differentiated, endometrioid endometrial
cancer: A gynecologic cancer inter-group (GCIG) study. J Gynecol
Oncol. 31(e74)2020.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Park JY, Kim DY, Kim TJ, Kim JW, Kim JH,
Kim YM, Kim YT, Bae DS and Nam JH: Hormonal therapy for women with
stage IA endometrial cancer of all grades. Obstet Gynecol.
122:7–14. 2013.PubMed/NCBI View Article : Google Scholar
|
